Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.71 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212378 | 0.84 | PDPK1 (0.71) | PDPK1PKMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4208195 | 0.83 | PDPK1 (0.74) | PDPK1GRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1850150 | 0.83 | PDPK1 (1.00) | PDPK1GRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4213459 | 0.81 | PDPK1 (0.66) | PDPK1PKMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4215734 | 0.81 | PKM (0.67) | PDPK1GRM1PKMNPC1RAB9A | |
| SCHEMBL4213637 | 0.77 | PDPK1 (0.72) | PDPK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17969217 | 0.75 | PDPK1 (0.74) | PDPK1GRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4208731 | 0.72 | PDPK1 (0.56) | PDPK1PKMIDO1PDGFRB | |
| SCHEMBL15845961 | 0.68 | IP6K1 (0.68) | RAB9AIDO1PIM1CLK4AURKA | |
| SCHEMBL13945506 | 0.68 | IDO1 (0.57) | IDO1CHEK1PARP1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PDPK1 13/4885GRM1 4614/4885PKM 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.